Cuprimine Related Published Studies
Well-designed clinical trials related to Cuprimine (Penicillamine)
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. [2004.02]
The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. [2001.03]
D-penicillamine is not an effective treatment in systemic sclerosis. [2001]
Evaluation of antineutrophil cytoplasmic antibody seroconversion induced by minocycline, sulfasalazine, or penicillamine. [2000.11]
Penicillamine in the treatment of systemic sclerosis. [1999.10]
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. [1999.06]
Intention-to-treat analysis of 200 patients with rheumatoid arthritis 12 years after random allocation to either sulfasalazine or penicillamine. [1998.10]
A long-term five-year randomized controlled trial of hydroxychloroquine, sodium aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritis. [1998.09]
A comparison between bucillamine and D-penicillamine in the treatment of rheumatoid arthritis. [1997]
D-penicillamine in early rheumatoid arthritis: experience from a 2-year double blind placebo controlled study. [1996.11]
Long term survival in Indian childhood cirrhosis treated with D-penicillamine. [1996.01]
Reversal of Indian childhood cirrhosis by D-penicillamine therapy. [1995.01]
Penicillamine in rheumatoid arthritis. A problem of toxicity. [1992.01]
Long-term evaluation of penicillamine or cyclofenil in systemic sclerosis. Results from a two-year randomized study. [1992]
Comparison of cyclosporine and D-penicillamine for rheumatoid arthritis: a randomized, double blind, multicenter study. [1991.06]
Toward a rational therapeutic strategy for arachnoiditis. A possible role for d-penicillamine. [1991.02]
A study of adjunctive copper sulphate treatment in patients with rheumatoid arthritis who have relapsed while taking D-penicillamine. [1991.01]
Degree and extent of response to sulphasalazine or penicillamine therapy for rheumatoid arthritis: results from a routine clinical environment over a two-year period. [1990.04]
OM-8980 and D-penicillamine in the treatment of rheumatoid arthritis. A 12-month double-blind randomized study. [1990]
Sulphasalazine versus penicillamine in the treatment of rheumatoid arthritis. [1989]
Clinical investigation in Duchenne muscular dystrophy: penicillamine and vitamin E. [1988.11]
Prospective trial of penicillamine in primary sclerosing cholangitis. [1988.10]
Clinical trials of penicillamine in Indian childhood cirrhosis. [1987.11]
Effects of sulphasalazine on faecal flora in patients with rheumatoid arthritis: a comparison with penicillamine. [1987.10]
Well-designed clinical trials possibly related to Cuprimine (Penicillamine)
Criteria for improvement in rheumatoid arthritis: alternatives to the American College of Rheumatology 20. [2004.05]
The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma. [2004.04]
The development and evaluation of a drug information leaflet for patients with rheumatoid arthritis. [2003.01]
Effect of patient education on adherence to drug treatment for rheumatoid arthritis: a randomised controlled trial. [2001.09]
Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands. [2000.06]
The Fifth Carlos E. Rubio Memorial Lecture. Sclerosing cholangitis: pathogenesis, pathology, and practice. [1999.03]
Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. [1999.03]
Influence of methotrexate on radiographic progression in rheumatoid arthritis: a sixty-month prospective study. [1997.05]
Time course of histological progression in primary biliary cirrhosis. [1996.01]
[A prospective study of plasma exchange in the treatment of diffuse scleroderma] [1995.09]
Endpoint measures in rheumatoid arthritis clinical trials: group summary and individual patient analysis. [1994.12]
Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis. [1993.08]
[A comparative controlled trial of 2 administration modalities of tiopronin in rheumatoid arthritis] [1993.05]
Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. [1992.03]
Cholangiocarcinoma complicating primary sclerosing cholangitis. [1991.01]
Double blind placebo controlled trial of pulse treatment with methylprednisolone combined with disease modifying drugs in rheumatoid arthritis. [1990.08.04]
Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. [1990.04]
Reversible nephrotoxicity of cyclosporine in rheumatoid arthritis. [1990.01]
Characteristics of responders and nonresponders to slow-acting antirheumatic drugs in juvenile rheumatoid arthritis. [1988.01]
Combination therapy with pulsed methylprednisolone in rheumatoid arthritis. [1985.11]
Other research related to Cuprimine (Penicillamine)
A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset. [2008.05]
A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset. [2008.02.16]
Bone mineral density of children with Wilson disease: efficacy of penicillamine and zinc therapy. [2008.02]
Withdrawal of penicillamine from zinc sulphate-penicillamine maintenance therapy in Wilson's disease: promising, safe and cheap. [2008.01.15]
Effect of penicillamine and zinc on iron metabolism in Wilson's disease. [2007.12]
D-Penicillamine-induced ANCA-associated crescentic glomerulonephritis in Wilson disease. [2007.11]
Effect of oral D-penicillamine vs. colchicine on experimentally induced peritoneal adhesions in rats. [2007.10]
Effect of oral d-penicillamine vs. colchicine on experimentally induced peritoneal adhesions in rats. [2007.06.05]
D-Penicillamine administration and the incidence of retinopathy of prematurity. [2007.02]
Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease. [2007.02]
Orally administered penicillamine is a potent inhibitor of neointimal and medial thickening in porcine saphenous vein-carotid artery interposition grafts. [2007.02]
Liquid chromatography/tandem mass spectrometry determination of (4S,2RS)-2,5,5-trimethylthiazolidine-4-carboxylic acid, a stable adduct formed between D-(-)-penicillamine and acetaldehyde (main biological metabolite of ethanol), in plasma, liver and brain rat tissues. [2007]
Systematic review and meta-analysis: D-Penicillamine vs. placebo/no intervention in patients with primary biliary cirrhosis--Cochrane Hepato-Biliary Group. [2006.12]
Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. [2006.10]
Penicillamine administration reverses the inhibitory effect of hyperhomocysteinaemia on endothelium-dependent relaxation in the corpus cavernosum in the rabbit. [2006.08]
Voluntary ethanol consumption decreases after the inactivation of central acetaldehyde by d-penicillamine. [2006.07.15]
Angiostatin generating capacity and anti-tumour effects of D-penicillamine and plasminogen activators. [2006.06.05]
Penicillamine administration reverses the inhibitory effect of hyperhomocysteinaemia on endothelium-dependent relaxation and superoxide formation in the aorta of the rabbit. [2006.02.15]
A pilot trial testing the feasibility of administering D-penicillamine to extremely low birth weight neonates. [2006.02]
[Penicillamine-induced bronchiolitis obliterans diagnosed by transbronchial lung biopsy] [2006.02]
D-penicillamine for primary sclerosing cholangitis. [2006.01.25]
Efficacy and safety of bucillamine, a D-penicillamine analogue, in patients with active rheumatoid arthritis. [2006]
Single intratumoral injection of long-acting benzyl ester of D-penicillamine inhibits the growth of melanoma tumor in mice. [2005.08]
Elastosis perforans serpiginosa secondary to D-penicillamine therapy with coexisting cutis laxa. [2005.07]
Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. [2005.07]
D-Penicillamine improved laparoscopic and histological findings of the liver in a patient with Wilson's disease: 3-year follow-up after diagnosis of Coombs-negative hemolytic anemia of Wilson's disease. [2005.06]
Penicillamine induced pseudoxanthoma elasticum with elastosis perforans serpiginosa. [2005.05]
Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. [2005.02]
Improvement in liver pathology after 4 months of D-penicillamine in 5 doberman pinschers with subclinical hepatitis. [2005.01]
Decline of anti-desmoglein 1 IgG ELISA scores by withdrawal of D-penicillamine in drug-induced pemphigus foliaceus. [2005.01]
Elastosis perforans serpiginosa associated with pseudo-pseudoxanthoma elasticum during treatment of Wilson's disease with penicillamine. [2005]
Synthesis and evaluation of long-acting D-penicillamine derivatives. [2005]
D-penicillamine for primary biliary cirrhosis. [2004.10.18]
Infant with severe penicillamine embryopathy born to a woman with Wilson disease. [2004.07.30]
D-penicillamine-induced pemphigus successfully treated with combination therapy of mizoribine and prednisolone. [2004.07]
Plasma D-penicillamine redox state evaluation by capillary electrophoresis with laser-induced fluorescence. [2004.04.25]
Tolerance induced by low dose D-penicillamine in the brown Norway rat model of drug-induced autoimmunity is immune-mediated. [2004.01]
[Minimal changes nephrotic syndrome associated to penicillamine treatment] [2004]
Transient fetal myelosuppressive effect of D-penicillamine when used in pregnancy. [2003.12]
The nitric oxide donor S-nitroso-N-acetylpenicillamine (SNAP) increases free radical generation and degrades left ventricular function after myocardial ischemia-reperfusion. [2003.12]
Epidermolysis bullosa acquisita-like reaction associated with penicillamine therapy for sclerodermatous graft-versus-host disease. [2003.12]
A case of penicillamine-induced dermopathy. [2003.09]
Goodpasture-like syndrome induced by D-penicillamine in a patient with systemic sclerosis: report and review of the literature. [2003.07]
Neurologic deterioration in a child with Wilson's disease on penicillamine therapy. [2003.05]
Effect of hypoxia on vasodilator responses to S-nitroso-N-acetylpenicillamine and levcromakalim in guinea pig basilar artery. [2003.05]
[Treatment of Wilson's disease with penicillamine and zinc salts: a follow-up study] [2003.02]
D-penicillamine and plasmapheresis in acute liver failure secondary to Wilson's disease. [2003.01]
Treatment of chronic haemophilic synovitis in humans with D-penicillamine. [2003.01]
Treatment of primary Sjogren's syndrome with D-penicillamine: a pilot study. [2002.11]
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. [2002.11]
Red blood cell copper, zinc superoxide dismutase activity is higher in Alzheimer's disease and is decreased by D-penicillamine. [2002.08.30]
[Appropriate administration schedule of D-penicillamine for pediatric Wilson's disease patients based on urinary copper excretion] [2002.08]
D-penicillamine treatment for lipoid proteinosis. [2002.07]
Antithymocyte globulin in the treatment of D-penicillamine-induced aplastic anemia. [2002.05]
Clinical and histological spectrum of elastotic changes induced by penicillamine. [2002.05]
Breast enlargement induced by D-penicillamine. [2002.03]
d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients. [2002.01]
|
